Neointimal formation is reduced after arterial injury in human crp transgenic mice

Atherosclerosis

Volumn 201, Issue 1, 2008, Pages 85-91

  Danenberg, Haim D ^a,b   Grad, Etty ^a   Swaminathan, Rajesh V ^b   Chen, Zhiping ^c   Seifert, Philip ^b   Szalai, Alexander J ^d   Lotan, Chaim ^a   Simon, Daniel I ^b,c   Edelman, Elazer R ^b,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Angioplasty; C reactive protein; Neointima; p38 MAPK

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THROMBOSIS; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM;

ANGIOPLASTY; ANIMALS; APOPTOSIS; C-REACTIVE PROTEIN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; FIBRINOLYTIC AGENTS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; THROMBOSIS; TUNICA INTIMA;

EID: 54049133705     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.01.013     Document Type: Article

References (46)

1. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
2. Devaraj S., Xu D.Y., and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107 (2003) 398-404
3. Danenberg H., Szalai A., Swaminathan R., et al. Increased thrombosis following injury in human C-reactive protein transgenic mice. Circulation 108 (2003) 512-515
4. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 38 (2001) 189-197
5. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197
6. Buffon A., Liuzzo G., Biasucci L.M., et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 34 (1999) 1512-1521
7. Walter D.H., Fichtlscherer S., Sellwig M., et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 37 (2001) 839-846
8. Versaci F., Gaspardone A., Tomai F., et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study). J Am Coll Cardiol 40 (2002) 1935-1942
9. Horne B.D., Muhlestein J.B., Strobel G.G., et al. Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention. Am Heart J 144 (2002) 491-500
10. Dibra A., Mehilli J., Braun S., et al. Association between C-Reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 114 (2003) 715-722
11. Chan A.W., Bhatt D.L., Chew D.P., et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 107 (2003) 1750-1756
12. Wang D., Oparil S., Chen Y., et al. Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 25 (2005) 2094-2100
13. Reis E., Smyth S., and Coller B. Mouse model of transluminal femoral artery injury. In: Simon D., and Rogers C. (Eds). Contemporary Cardiology: Vascular Disease and Injury: Preclinical Research (2001), Humana Press, Totowa, NJ 103-113
14. Szalai A.J., and McCrory M.A. Varied biologic functions of C-reactive protein: lessons learned from transgenic mice. Immunol Res 26 (2002) 279-287
15. Lim M.Y., Wang H., Kapoun A.M., et al. p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells. J Mol Cell Cardiol 37 (2004) 1111-1114
16. Folsom A.R., Pankow J.S., Tracy R.P., et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 88 (2001) 112-117
17. Khera A., de Lemos J.A., Peshock R.M., et al. Relationship between C-reactive protein and subclinical atherosclerosis: the dallas heart study. Circulation 113 (2006) 38-43
18. Hirschfield G.M., Gallimore J.R., Kahan M.C., et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. PNAS 102 (2005) 8309-8314
19. Paul A., Ko K.W., Li L., et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109 (2004) 647-655
20. Reifenberg K., Lehr H.-A., Baskal D., et al. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer?. Arterioscler Thromb Vasc Biol 25 (2005) 1641-1646
21. Tennent G.A., Hutchinson W.L., Kahan M.C., et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE(-/-) mice. Atherosclerosis (2007)
22. Verma S., Devaraj S., and Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 113 (2006) 2135-2150
23. Taylor K.E., Giddings J.C., and van den Berg C.W. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 25 (2005) 1225-1230
24. Lafuente N., Azcutia V., Matesanz N., et al. Evidence for sodium azide as an artifact mediating the modulation of inducible nitric oxide synthase by C-reactive protein. J Cardiovasc Pharmacol 45 (2005) 193-196
25. Liu C., Wang S., Deb A., et al. Proapoptotic, anti-migratory, anti-proliferative, and anti-angiogenic effects of commercial C-Reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ Res 97 (2005) 135-143
26. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106 (2002) 1439-1441
27. Verma S., Wang C.H., Li S.H., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106 (2002) 913-919
28. Verma S., Kuliszewski M.A., Li S.-H., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109 (2004) 2058-2067
29. Khreiss T., Jozsef L., Potempa L.A., and Filep J.G. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109 (2004) 2016-2022
30. Danenberg H., Welt F., Walker M., et al. Systemic inflammation induced by lipopolysaccharide increases neointimal formation following balloon and stent injury in rabbits. Circulation 105 (2002) 2917-2922
31. Woods T.C., Blystone C.R., Yoo J., and Edelman E.R. Activation of EphB2 and its ligands promotes vascular smooth muscle cell proliferation. J Biol Chem 277 (2002) 1924-1927
32. Voisard R., Fischer R., Osswald M., et al. Aspirin (5 mmol/l) inhibits leukocyte attack and triggered reactive cell proliferation in a 3D human coronary in vitro model. Circulation 103 (2001) 1688-1694
33. Lovich M.A., and Edelman E.R. Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Proc Natl Acad Sci USA 96 (1999) 11111-11116
34. Swafford Jr. A.N., Bratz I.N., Knudson J.D., et al. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am J Physiol Heart Circ Physiol 288 (2005) H1786-H1795
35. Napoli C., Cirino G., Del Soldato P., et al. Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc Natl Acad Sci USA 98 (2001) 2860-2864
36. Gershov D., Kim S., Brot N., and Elkon K.B. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192 (2000) 1353-1364
37. Chen Z., Fukutomi T., Zago A.C., et al. Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation 106 (2002) 20-23
38. Shibata R., Kai H., Seki Y., et al. Inhibition of STAT3 prevents neointima formation by inhibiting proliferation and promoting apoptosis of neointimal smooth muscle cells. Hum Gene Ther 14 (2003) 601-610
39. Kew R., Hyers T., and Webster R. Human C-reactive protein inhibits neutrophil chemotaxis in vitro: possible implications for the adult respiratory distress syndrome. J Lab Clin Med 115 (1990) 339-345
40. Dobrinich R., and Spagnuolo P. Binding of C-reactive protein to human neutrophils. Inhibition of respiratory burst activity. Arthritis Rheum. 34 (1991) 1031-1038
41. Szalai A.J., Weaver C.T., McCrory M.A., et al. Delayed lupus onset in (NZB × NZW)F1 mice expressing a human C-reactive protein transgene. Arthritis Rheum 48 (2003) 1602-1611
42. Szalai A.J., Nataf S., Hu X.Z., and Barnum S.R. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 168 (2002) 5792-5797
43. Li S.H., Szmitko P.E., Weisel R.D., et al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 109 (2004) 833-836
44. Sawada M., Yanamoto H., Nagata I., et al. Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats. editorial comment. Stroke 30 (1999) 644-650
45. Ju H., Nerurkar S., Sauermelch C., et al. Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury. J Pharmacol Exp Ther 301 (2002) 15-20
46. Hutter R., Sauter B.V., Reis E.D., et al. Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. Circulation 107 (2003) 1658-1663